Table 6 DMD choice following suboptimal response to original treatment by anti-JCV antibody status (n = 205)
n (%) | Preferred replacing DMD | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regardless of anti-JCV antibody status | Anti-JCV antibody negative | ||||||||||||
SC IFNβ-1b | IM IFNβ-1a | Fingolimod | Natalizumab | Glatirameracetate | Other | SC IFNβ-1b | IM IFNβ-1a | Fingolimod | Natalizumab | Glatirameracetate | Other | ||
Current DMD | SC IFNβ-1b | – | 65 (31.7) | 119 (58.1) | 8 (3.9) | 13 (6.3) | 0 (0.0) | – | 67 (32.7) | 110 (53.7) | 16 (7.8) | 12 (5.9) | 0 (0.0) |
IM IFNβ-1a | 32 (15.6) | – | 149 (72.7) | 13 (6.3) | 11 (5.4) | 0 (0.0) | 34 (16.6) | – | 133 (64.9) | 21 (10.2) | 15 (7.3) | 2 (1.0) | |
Fingolimod | 28 (13.7) | 39 (19.0) | – | 107 (52.2) | 29 (14.2) | 2 (1.0) | 29 (14.2) | 35 (17.1) | – | 116 (56.6) | 23 (11.2) | 2 (1.0) | |
Natalizumab | 20 (9.8) | 18 (8.8) | 90 (43.9) | – | 59 (28.8) | 18 (8.8) | 18 (8.8) | 17 (8.3) | 105 (51.2) | – | 52 (25.4) | 13 (6.3) | |
Glatiramer acetate | 30 (14.6) | 34 (16.6) | 85 (41.5) | 43 (21.0) | – | 13 (6.3) | 26 (12.7) | 30 (14.6) | 88 (42.9) | 52 (25.4) | – | 9 (4.4) | |